Abstract:Background: Cells of the immune system can inhibit tumor growth and progression; however, immune cells can also promote tumor cell growth, survival, and angiogenesis as a result of the immunosuppressive microenvironments. In the last decade, a growing number of new therapeutic strategies focused on reversing the immunosuppressive status of tumor microenvironments (TMEs), to reprogram the TME to be normal, and to further activate the antitumor functions of immune cells. Most of the “hot tumors” are encompassed with M2 macrophages promoting tumor growth, and the accumulation of M2 macrophages into tumor islets leads to poor prognosis in a wide variety of tumors. Summary: Therefore, how to uncover more immunosuppressive signals and to reverse the M2 tumor-associated macrophages (TAMs) to M1-type macrophages is essential for reversing the immunosuppressive state. Except for reeducation of TAMs in the cancer immunotherapy, macrophages as central effectors and regulators of the innate immune system have the capacity of phagocytosis and immune modulation in macrophage-based cell therapies. Key Messages: We review the current macrophage-based cell therapies that use genetic engineering to augment macrophage functionalities with antitumor activity for the application of novel genetically engineered immune cell therapeutics. A combination of TAM reeducation and macrophage-based cell strategy may bring us closer to achieving the original goals of curing cancer. In this review, we describe the characteristics, immune status, and tumor immunotherapy strategies of macrophages to provide clues and evidences for future macrophage-based immune cell therapies.

Modulating and Imaging Macrophage Reprogramming for Cancer Immunotherapy

A Chimera Antigen Receptor Containing TLR4 Signaling Domain Enhances CAR-iMACs Polarization and Potency against Solid Tumors

Macrophage-Based Combination Therapies as a New Strategy for Cancer Immunotherapy

Molecular imaging of tumor-associated macrophages in cancer immunotherapy

Modulating Repolarization of Tumor-Associated Macrophages with Targeted Therapeutic Nanoparticles as a Potential Strategy for Cancer Therapy

Macrophage-modulating nanomedicine for cancer immunotherapy

New insights into the role of macrophages in cancer immunotherapy

Targeting immune checkpoints on tumor-associated macrophages in tumor immunotherapy.

Engineering Macrophages for Cancer Immunotherapy and Drug Delivery

Metabolic reprogramming of macrophages in cancer therapy

Reprogramming Tumor Associated Macrophages Toward M1 Phenotypes with Nanomedicine for Anticancer Immunotherapy

Mir-182 Targeting Reprograms Tumor-Associated Macrophages and Limits Breast Cancer Progression

Targeting the macrophage immunocheckpoint: a novel insight into solid tumor immunotherapy

Leveraging macrophages for cancer theranostics

Harnessing and Enhancing Macrophage Phagocytosis for Cancer Therapy

Advances in Engineered Macrophages: A New Frontier in Cancer Immunotherapy

Tumor-associated macrophages: A promising target for a cancer immunotherapeutic strategy

Engineering macrophages and their derivatives: A new hope for antitumor therapy

Harnessing the innate immune system by revolutionizing macrophage-mediated cancer immunotherapy

Harnessing Anti‐tumor and Tumor‐tropism Functions of Macrophages Via Nanotechnology for Tumor Immunotherapy

CAR Macrophages: a promising novel immunotherapy for solid tumors and beyond